• Samsung Biologics executive Im Hee-gyun sold all 11 securities carrying subscription rights on October 27, 2026.
• The securities had been transferred from an employee stock ownership association account to his personal account on October 22.
• His reported securities holdings stood at zero, representing a 0% stake, as of October 28.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261028000425), on October 28, 2026, and is solely responsible for the information contained therein.